Category: drug-screening

The technology presents a novel structural modification of an existing first generation Grp94 selective inhibitor to generate a second generation Grp94-specific scaffold which has greater affinity and selectivity compared to existing inhibitors and prevents unfavorable binding of other Hsp90 isoforms.

Category(s):

Unique chemical derivatives invented by University of Kansas (KU) researchers that could be used to detect inhibitors of cellular efflux transporters and other agents. 

Category(s):

Novel ligands designed to activate mu opioid receptors and provide analgesic effects without opioid-related side effects, providing specific insight into the cellular impact of opioid receptor-based activation as related to pain medications.  These ligands could be used as a tool to negate drug tolerance and dependence as well as other adverse side effects.

This invention provides an improved method for producing a novel interfacing capillary device that is less costly and more durable than existing sheathless devices.  This simplified production method does not require sample dilution, etching, or precision hand tools, and is automated and reproducible.  

Use of a genetic dereplication strategy eliminates major known SM biosynthetic pathways in Aspergillus nidulans, reducing the complexity of SM profiles and activating an abundance of silent SM gene clusters to enable identification of a new pool of fungal products for drug discovery.

Subcategory(s):

Broad based label-free systems identify protein stabilizers at physiological or near physiological conditions that specifically inhibit Bacterial Toxin or Viral entry into cells. 

Category(s):

PEPCK is an enzyme critical in the process of gluconeogenesis whose inhibition could be used to treat hyperglycemia and diabetes.

Category(s):

The present invention employs a novel use of logic and data analysis tools to improve the efficiency of drug discovery.

Subcategory(s):
Currently there are no good treatment options for individuals diagnosed with pancreatic cancer. As a result, the two year survival rate after diagnosis is only 10%. Thus, novel therapeutic agents are needed that effectively treat pancreatic cancer.
 
The current invention is novel crocetinic analogs that have showed reduced proliferation of pancreatic cancer cells and inhibited metastasis in pancreatic cancer mouse model. These analogs carry out this function by targeting key factors that function in pancreatic cancer tumor growth. The analogs are stable and non-toxic.
Category(s):

The current invention is a novel class of compounds that function as KOR antagonists.  Because KOR activation has been linked to depression and anxiety related disorders, this novel class of compounds may be used in the development of therapies to treat these mental disorders

Category(s):

Pages


Events
KU Today